Kaneka Obtains Positive Results in Preclinical Trials of Drug Eluting Stent.
The Company commissioned Thoraxcenter, a hospital in the Netherlands, to conduct full-scale trials using pigs. The hospital confirmed that Kaneka's DES effectively inhibits blood vessel inflammation and endothelial proliferation. Furthermore, the DES helps accelerate the healing of endothelium. Based on these findings, Kaneka expects that the DES may substantially reduce the risk of stent thrombosis.
Kaneka's DES, which uses cobalt chromium alloy for a stent, consists of tacrolimus, an immunosuppressant by Astellas Pharma, and biodegradable polymer.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jun 16, 2006|
|Previous Article:||Ako Kasei Confirms that High Mineral Water Helps Suppress Helicobacter Pylori.|
|Next Article:||Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection.|